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ABSTRACT
Gastrointestinal alterations in two mouse models that are associated with social behavior deficits

By
Gracie Leamon

The gastrointestinal (GI) tract is a diverse habitat for multiple microorganisms.
Disturbances in the microbiome of the GI tract have been associated with psychiatric disorders
including autism spectrum disorder (ASD). Individuals with ASD, when compared to
neurotypical individuals, have demonstrated differing gut species. Also, it has been shown that
microbial transplant therapies impact ASD symptoms in patients. Animal models of behaviors
associated with ASD might offer insight for the actual role these microbial differences may
occupy regarding symptoms. Unfortunately, ASD does not have an accepted animal model
where the GI alterations have been thoroughly explored. In this study, we sought to determine if
the microbiome and other GI alterations were observed in two potential mouse models of social
behavior deficits, the genetic BTBR T+Itpr3tf/J (BTBR) mouse strain and an environmental
mouse strain consisting of offspring of valproic acid (VA) treated pregnant controls. Both mouse
models have been shown to exhibit social and repetitive behaviors that are found in human ASD.
Using the Illumina MiSeq, we were able to identify taxonomy associated with 16S ribosomal
DNA sequences extracted from fecal matter. We were able to compare the sequencing results
from the two affected strains and a control C5BL/6J mouse strain for both female and male
animals using the Qiagen CLC Genomics Workbench software. Overall, microbiome
composition was found to be significantly different between the male control animals (N=6)
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when compared to the VA (N=5; p-value=.00216; F-score 11.20904) or the BTBR (N=7; pvalue=.00216; F-score 18.47839) males using a PERMANOVA analysis. This was replicated in
female groups where composition significantly differed between the control (N=14) and VA
(N=14; p-value=.00001; F-score 3.53307) or BTBR (N=14; p-value=.00001; F-score 11.23443)
females. Additionally, short-chain fatty acid analysis using gas capillary-based chromatography
was used to examine acetate, butyrate, propionate, and valerate levels in feces. Only valerate
levels were significantly lower (p<.05) in BTBR males (N=18) when compared to control males
(N=13). In females, both acetate (p<.05) and propionate (p<.01) were significantly decreased in
BTBR females (N=13) when compared to control female mice (N=14). Additionally, we
compared the thickness of the intestinal mucosal and muscular layers in the three groups for
males and females. Across all three groups, neither male nor female showed notable significant
differences in the thickness of either the muscular or mucosal layers. This data will be useful in
continuing to identify the complex pathologies present in potential animal models used for
research into social deficit disorders.
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INTRODUCTION
Autism Spectrum Disorder Diagnosis
Autism Spectrum Disorder (ASD) is a neurological disease that is characterized by
deficits in social behaviors as well as relative behaviors. These behaviors include but are not
limited to lack of eye contact, inability to control and distinguish emotions, and overall activity
restrictions (Park, 2016). ASD is commonly diagnosed at approximately three years of age and
has a four to one ratio in the diagnosis of males to females (de Giambattista, 2021). This disorder
can only be identified by behavioral deficiencies. Currently, there is no treatment exclusively for
ASD symptoms. Most likely the disorder is affected by countless variables including a genetic
etiology; however, it is possible that environmental factors may influence the development.
Biomarkers associated with ASD have not been identified, but physiological markers such as
microbiota profiles and metabolic function markers are being explored (Peralta-Marzal, 2021).
The identification of specific biomarkers and the etiology of the disorder are lacking in the ASD
literature (Peralta-Marzal, 2021).
ASD Brain Pathology
The brain pathology of ASD is an essential part of research efforts, but has not been
completely characterized. Neuropathological abnormalities between neurotypical and ASD
individuals have been observed in both cortical and non-cortical regions of the brain. Early
studies like one done in 2015 indicated that ASD has an increased head circumference and total
brain volume (TBV) when compared to typically developing subjects by use of MRI. The same
study used twenty-seven ASD patients ranging from one to thirty-eight years of age to find
increased head circumference in both males and females. Similarly, increased TBV was found
using forty-four males and females ages two to forty years old with a structural MRI scan
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(Sacco, 2015). In addition, increases in both gray and white matter have been shown in children
with ASD in a cohort study using twenty-seven subjects of eighteen males and nine females
ranging from four to sixty-nine years of age (Wegiel, 2010). Disruption in neuronal signaling
during brain maturation likely plays a key role in the pathophysiology of ASD. Interestingly,
clinical symptoms and traits have been linked to disruptions in unique brain areas in ASD. For
instance, brain areas associated with verbal communication, such as the Broca and Wernicke’s
areas, demonstrated less brain activity in ASD children when compared to neurotypical children
in a 2008 study of thirty-five subjects (twenty-nine males and seventeen females) ranging from
two to three years old using functional magnetic resonance imaging (fMRI) (Redcay, 2008).
Gastrointestinal Disorders in ASD
Gastrointestinal (GI) alterations are associated with ASD. Studies have shown that it is
not uncommon for children with ASD to have GI inflammation, gut microbiota variation, and
occasional gut infections (Ristori , 2019). Dysbiosis is a notable GI disorder associated with
ASD (Mangolia, 2021). Dysbiosis has been coined as a term describing the disturbance in the
gut microbiota equilibrium caused by an imbalance in the microbial population, metabolic,
composition or distribution change (DeGruttola, 2016) Dysbiosis can consequently lead to
increased permeability of the intestinal tract (Ristori, 2019). Another disorder closely linked to
dysbiosis is irritable bowel syndrome (IBS). A 2017 study using sixty adult subjects (fifty-four
males and ninety-five females) found that IBS symptom severity was associated with dysbiosis
and intestinal permeability (Tap, 2017). Symptoms associated with IBS such as inflammatory
systemic responses as a result of increased permeability have been found in ASD individuals
(Ristori, 2019). It seems likely that intestinal permeability deficits are associated with ASD. It
is tempting to speculate that bacterial products are able to travel across the gut barrier into the
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bloodstream and past the blood-brain-barrier (BBB). Thus, increased permeability is perhaps a
noteworthy event in ASD.
Gut-Brain Axis
The association of gut disorders in the neurodevelopmental disorder ASD has prompted
investigators to contemplate the relationship between the digestive and central nervous systems.
The gut-brain axis can be described as the intimate connection between the GI system and the
central nervous system (CNS). The brain and the GI system are able to communicate and
influence one another. They can be mediated by a plethora of pathways that are neural,
endocrine, immune, and metabolic in nature and are not fully understood (Mörkl, 2020). These
bacteria and other metabolites are able to pass over the BBB due to its permeability and can
contribute to the CNS function and disease (Rutsch, 2020).
In psychiatric disorders, the gut-brain axis can be disrupted by dysbiosis in the gut in
terms of altered permeability of the BBB and neuroinflammation. These events can impact the
central nervous system’s (CNS) homeostasis by changes in inflammation. Inflammation in the
brain can occur due to stress that is accompanied by the presence of a different bacterial profile
in the gut and the of bacteria producing inflammatory metabolites (Rutsch, 2020). The alteration
of bacterial species in the gut and related products can directly affect individual behaviors. It has
been shown that ninety percent of serotonin required for mood, behavior, sleep, and several other
functions within the CNS and gastrointestinal (GI) tract is produced in the gut (Rutsch, 2020).
A disruption of CNS blood-brain barrier permeability and inflammation can be related to the gut.
Additionally, it has been shown that pathogens and aberrant molecules are able to enter the CNS
via the blood-brain barrier (Osadchiy, 2019). Consequently, it seems that gut microbial
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alterations and increased BBB permeability could be involved in the pathophysiology of
psychiatric and neurodevelopmental disorders.
Various therapeutic research has begun to identify the outcomes of modifying the gutbrain axis. For instance, probiotics have been found to diversify the microorganisms available in
the gut for transportation. And in a similar case, prebiotics have been shown to lead to
modulation in brain function and behavior as well (Mörkl, 2020). It is thought that diet can
clinically improve the gut microbial function in adults by individualized treatments following
dysbiosis specificity (Osadchiy, 2019). Personal therapies of probiotics, prebiotics, and diet are
hypothesized as an effective way to modulate a disrupted gut-brain axis as a result of dysbiosis
(Osadchiy, 2019). The human body houses trillions of cells that contribute to the benefit and
detriment of human life. The gut holds the densest amount of these microbial cells (Milani,
2017). Over 70% of the microorganisms making up the gut microbiome come from the colon
(Hold, 2002). The gut microbiome is influenced by factors including genetics, environment, and
individual nutrition (Mukherjee, 2018). Per the Human Microbiome Project, a healthy gut is
defined as “a core set of microbial taxa universally present in healthy individuals who lack overt
disease phenotypes under the hypothesis that the absence of such microbes would indicate
dysbiosis” (Redondo-Useros, 2020).
Gut Microbiota Alterations in ASD
In addition to cognitive behaviors and functions, individuals on the ASD spectrum have
been observed to have an altered gut microbiome when compared to the microbiome of
neurotypical individuals. Apart from overall contrasting microbiomes, the most notable
difference in the quantities of SCFAs found in the gut that are able to cross the BBB into the
CNS (Macfabe, 2012). There is interest in the possibility that altering GI tract factors in terms of
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microbiota could improve ASD symptoms. This correlation can be seen in a study using
microbiota transfer therapy (MTT) in eighteen children seven to eight years old. The results
indicate that this 10-week antibiotic treatment improved GI factors and ASD symptoms on
average (Kang, 2017). Further understanding and acknowledgement of the importance of the gut
microbiota and its effect on the brain is an important element in understanding ASD.
Various analyses of fecal matter, serum, and urine between neurotypical controls and ASD
individuals have resulted in comparable differences in terms of what molecules are present
within the microbiome. (Sharon, 2019). The gut serves to be an impactful conduit in other
disorders such as obesity, IBS, allergies, and other non-communicable diseases (NCD) as shown
in a 2015 open study (West, 2015). The specificity of the microbes present in individuals are 1/3
similar in all individuals and 2/3 specific in every individual almost like a microbial
fingerprint.(Salami M. 2021). A study done in 2015 sequenced 242 individual DNA and found
distinct differences in personal microbiota (Franzosa, 2015). Thus, the differences in the gut of a
neurotypical individual and an ASD individual are vital to understand, as an imbalance may lead
to behaviors of the disorder (Grace Lucas, 2018).
Role of Metabolites
Venegas defines short-chain fatty acids (SCFAs) as “carboxylic acids with aliphatic tails
of 1-6 carbons...produced by anaerobic fermentation of dietary fibers in the intestine” (Venegas,
2019). They are significant metabolites that can have positive effects on the intestines and can
affect processes such as gene expression, cell proliferation and differentiation. SCFAs act as
important energy and signaling molecules that contribute to an individual’s overall health by
improving metabolism and glycemic control (Koh, 2016). Though not fully understood, SCFAs
may hold a key role in regulating the gut-brain axis. In recent studies, there have been
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differentiations between the gut microbiota in association with SCFAs analyzed in fecal matter
of ASD individuals in comparison to neurotypical A 2019 study’s results showed that between
fifty 3-6 year old children, there was a significant decrease in acetate and significantly high
increase in valerate in the ASD children observed (Liu, 2019).
Notable SCFAs associated with impacts on human health include acetate, propionate,
butyrate, and valerate. Acetate, propionate, and butyrate are the most abundant SCFAs and are
most commonly used in studies when researching certain metabolites that can cross the BBB and
come in intimate contact with the brain (Wenzel, 2020). Valerate, a five-carbon chain, is
included in many studies as well despite a lack of abundance. Acetate, a two-carbon chain,
encourages cholesterol production in the liver and has a key role in health but, additionally,
neurological diseases (Lobzhanidze, 2020). It has been shown that increasing propionate, a threecarbon chain, can impact social behaviors in animal models (Frye, 2015). It also affected gastric
motility, smooth muscle contractions, and dilation of intestinal mucosa in these same animals
(Frye, 2015). Butyrate, a four-carbon chain, can impact the gut barrier by way of an increase in
transepithelial electrical resistance (TER) and insulin permeability decrease. These factors
encourage the gut function (Peng, 2007). Butyrate has been shown to elevate occludin protein
expression, a transmembrane protein that is linked to decreasing and revitalizing BBB
permeability (Braniste, 2014). Valerate has been shown to be elevated in young children with
ASD when compared to typically developing control subjects in a study of forty-one males and
nine females (Liu, 2019). Interestingly, valproate or valproic acid is commonly used as an
antiseizure medicine and does seem to have an increased incidence of risk in children whose
mothers were exposed during pregnancy (Ornoy, 2009). Notably, data published concerning
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SCFAs is not always consistent concerning levels of propionate, acetate, butyrate, and valerate
associated with ASD (Liu, 2019).
Pathology of the Digestive System in ASD
The purpose of the intestinal lumen, notably the mucosal and muscular layers, is to filter
harmful and harmless stimuli (Thoo, 2019). There are four general layers to the digestive tract:
the mucosa, submucosa, muscular layer, and serous layer. The mucosa is the innermost layer of
the tract that lines the lumen consisting of connective tissue and smooth muscle called the
epithelium. The submucosa encloses the mucosa in loose connective tissue. It contains the blood
vessels, lymphatic vessels, nerves, and occasional glands (reference general structure of the
digestive). The muscular layers, otherwise known as the muscular propria, aid in the
transportation of food through the gut and lie just beyond the submucosa. Finally, the serosa is
the very outermost layer made up of loose connective tissue whose primary role is to reduce
friction. The intestinal lumen, attributed to its anatomical characteristics, is hypothesized to
contribute to the gut-brain axis.
The enteric nervous system (ENS) is the nervous system related to the intestinal tract. It
is a series of neurons that contribute to sensory and motor functions in the digestive tract. The
ENS plays a role in intestinal homeostasis and controls processes such as gut motility, secretion,
and blood flow and are able to interact with afferent/sensory neurons that travel to the CNS to
relay signals (Margolis, 2016). This network is arranged in the gut in two layers: the myenteric
and submucosal plexus. The myenteric plexus of muscular layers influences gut motility. The
submucosal plexus is responsible for secretion and blood flow within the intestines. Although
working through independent neuronal signals, the ENS has an intimate connection with the
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central nervous system through autonomic regulation. Both sympathetic and parasympathetic
signaling can influence ENS function.
Information associated with the parasympathetic division of the autonomic nervous
system can occur between the ENS and the vagus nerve. The vagus nerve is the tenth cranial
nerve whose cell bodies are housed in the brainstem and offers the most direct route for
communication between the digestive tract and the brain axis. It has extensive innervation
including many organs of the digestive system. The direct communication allows for the
stimulation of the vagus nerve to result in the activation of neurons in the CNS by way of gut
microbiota signaling. Another key CNS regulator of the gut is the sympathetic nervous system.
The sympathetic trunk relays direct efferent and afferent information between the ENS to the
CNS via the spinal cord (Furness, 2014). Though clear in its role as a conduit for gut-brain
signaling, more research is needed to identify specific CNS to ENS contributions to the
pathophysiology of neurological, neurodevelopmental, and psychiatric disorders.
The digestive system can become compromised and lead to pathogenic intestinal
symptoms including diarrhea, bloating, constipation, etc. as discovered in various neuro-related
disorders such as ASD, Parkinson’s disease (PD) and Alzheimer's disease (AD) (Fu, 2021,
Wang, 2011). A large study in 2011 was conducted to determine the prevalence in children with
autism of GI symptoms. The study found that diarrhea and constipation were significantly
correlated with ASD (Wang, 2011). In Parkinson’s Disease, probiotics were successful in
alleviating gastrointestinal symptoms such as bloating (Cassani, 2011). A meta-analysis of fiftysix studies concerning PD and AD found that there was indeed a relationship between these
diseases and intestinal disorders (Fu, 2020). The association of digestive system alterations with
neurological and neurodevelopmental disorders highlights the need to understand the actual
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microbiome makeup within the gut. The pathology and microbiota mechanisms and connections
are not widely understood; however, it has been observed that interruptions in the digestive
system are a direct result of gut microbiota instability and lack of diversity (Lombardi, 2018).
Mouse Models of ASD
A viable tool for exploring the relationship between brain and intestinal pathophysiology
of neurodevelopmental disorders is the use of animal models. However, it is noted in the
literature that animal models are only accepted for study when a defined behavior or event can be
identified for study. Animal models used in the study of neurodevelopmental or psychiatric
disorders have been highly criticized due to the complex nature of human behavior and neuronal
signaling between executive order brain areas. In ASD, animal models associated with behaviors
such as repetition, social deficits, and other impairments contributing to communication are
being investigated.
While no animal model has been accepted in the field of ASD study there are a few in the
literature that have emerged as potential candidates. The valproic acid (VA) model injects the
five-carbon SCFA valproic acid into pregnant mouse dams during mid-gestation (Kultima,
2004). Offspring from pregnant mouse dams injected with valproic acid demonstrate social
behavior deficits and repetitive behaviors (Yamaguchi, 2017). Interestingly, valproic acid or
valproate is commonly used as an anti-seizure medication. As mentioned previously, it was
observed that exposure to valproic acid during pregnancy resulted in an increased risk of ASD in
the children of these mothers (Nicolini, 2018). It was shown in a 2020 animal study that valproic
acid-treated rats demonstrated neuronal apoptosis resulting in neurotransmitter alterations
(Bittigau, 2002).
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The BTBR strain is another model that has been used to examine pathophysiological
differences associated with social behavior deficits. It is an inbred mouse strain of animals using
C57BL/6J with tan mice that exhibit low sociability and repetitive grooming (McTighe, 2013).
In addition, this strain exhibits abnormal immune responses (Queen, 2021). Originally, this strain
was bred for use in studies concerning abdominal obesity, insulin resistance, diabetes-induced
nephropathy and phenylketonuria (Queen, 2021). This model may be useful in exploring
disorders with social behavior deficits. Studies have shown altered gut permeability and colon
inflammation by altered cytokine patterns in adult female and male rats of BTBR when
compared to wild-type control samples (Cortetti, 2017). Though there is no accepted animal
model for ASD as of late, the BTBR strain is a promising one to use as the inbred strain elicits
mice with deficits in social behaviors.

Hypothesis:
The study described here compared C57BL/6 wild type mice to two different animal
models that have been associated with social behavioral deficits in an attempt to identify
intestinal pathology. We hypothesize that differences in the intestinal makeup present in the
mouse colon may include differences in gut microbiota, SCFA expression and thickness of
intestinal layers between at least one of the mouse models and wild type control mice.
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METHODS AND MATERIALS
Animals and Tissue Collection
Both male and female mice of C57BL/6 wild-type control mice, BTBR strain, and
valproic acid-treated used in all experiments were group-housed and fed ad libitum. All mice
used in the study were obtained from The Jackson Laboratories including C57BL/6J (strain
#000664) and BTBR T+ Itpr3tf/J (strain # 002282). For the valproic acid model, pregnant
C57BL/6J dams were injected with valproic acid (600 mg/kg; #4543; Sigma Aldrich; St. Louis,
MO) at gestational day 11. Females used in the study were from similar time periods, while the
males were obtained for two different batch dates. All animals used in this study were aged to
postnatal day 105 (P105). At P105 fecal matter was collected for approximately 14 days and
stored in -80°C ultra-low freezer immediately following collection. Intestinal tissue was
obtained at sacrifice and placed in 4% paraformaldehyde for 24 hours followed by storage in
70% ethanol at 4oC. All animal protocols were approved by the ETSU University Committee for
Animal Care (UCAC).
DNA Isolation
DNA isolations were performed using the Power Soil Pro extraction system from Qiagen
(#47014 Qiagen, Germantown, Maryland). Fecal matter used for DNA purification was between
75 to 150 mg total. DNA concentrations and OD 280/260 readings were obtained using
nanodrop 2200. Library construction and next-generation DNA sequencing was performed by
the Genomics Core Laboratory at the University of Tennesse Genomics Center using the
Illumina Miseq. The variable V3 and V4 region specific primers for the ribosomal subunit 16
were used in library construction.
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Analysis of DNA sequences
All data analysis was performed using the Qiagen CLC Genomics Workbench. The
DNA was trimmed and clustered into Operational Taxonomical Units (OTU) in which reads of
97% or more similarity represent a unit. These sequences were then aligned and sorted into the
different taxonomy classifications using the Green Genes Data Dank. Afterwards, OTUs were
analyzed to create alpha diversity plots, phylogenetic diversity analysis, beta diversity graphs, a
differential abundance analysis file and a PERMONOVA of beta diversity. There were a total of
14 wild type mice, 14 BTBR mice, 14 valproic acid female samples and 13 wild type control
mice, 15 BTBR, and 14 Valproic Acid male samples used for analysis.
SCFA Methodology
Approximately 500 mg of fecal sample was used for short-chain fatty acid identification
of acetate, propionate, butyrate, and valerate. Freeze drying of fecal samples was performed for
24-48 hours prior to analysis. The procedure for identifying SCFA acids using gas
chromatography was adapted from a previously described protocol (Schwiertz 2010). In brief,
approximately 80 mg of freeze sample remained after freeze drying and was added to 1 mL of
SCFA solution that contained oxalic acid (0.1 mol/L), sodium azide (40 mmol/L) and caproic
acid (0.1 mmol/L). Tubes was placed on shaker for one hour followed by centrifugation at 4,000
rpm for 20 minutes. Supernatant was removed and centrifuged again at 12,000 rpm for 15
minutes. Samples were analyzed using a Shimadzu GC2010 gas chromatograph machine that
obtained measurements through increasing the temperature from 50oC to 140oC using a ramp
rate of 15 degrees per minute. Following a five-minute hold at 140oC, the temperature then rose
at 10 degrees per minute until reaching 175oC with a three-minute hold at 160oC. Two replicates
were performed for each sample.
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Intestinal Sectioning and Staining
Large Intestine tissue from P105 male and female mice (P105) was stored in 70% ethanol
solution at 4oC until use. Each sample was cut into an approximately .5 cm diameter section and
placed in an embedding tissue cassette. The embedding process was performed by ETSU
Department of Pathology. Paraffin embedding was performed, and sections were obtained to
provide a cross-sectional view of each large intestine. The sections were then exposed to using a
hematoxylin and eosin solution for morphological identification of intestinal layers.
Intestinal Analysis
A Zeiss AxioObserver using an AxioVision 4.8 camera hookup was used to acquire all
images. Images were viewed using the Brightfield setting for a 5X objective. Image J software
provided by NIH was used to determine the distance of the tunica mucosa and tunica muscularis
for each section. The average muscular and mucosal measurements for each of the three groups
(Control, VA, and BTBR) in both male and females resulted from a total of 60 different animal
intestines made up of male controls (N=10), valproic acid (N=11), BTBR N=9, female controls
(N=10), valproic acid (N=10), and BTBR (N=10). Each animal has three cross-sections from the
colon for analysis. Every cross-section had 2-4 images to obtain the entire diameter. Each crosssection had a total of 8 muscular and mucosal measurements each. To ensure this quantity of
measurements stayed as similar as possible, cross-sections small enough to be captured in only
two images had 4 measurements taken for each layer per image. See Appendix Table 1 and
Table 7 to further analyze the quantity of animals, cross-sections, images, and measurements that
were taken for each individual animal. The table indicates that the number of measurements for
each layer relies heavily on the number of cross-sections. Averages for each layer were obtained
using the three different measurements for cross-sections from each subject. Each cross-section
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that made up a specific animal’s intestine was given an average muscular and mucosal
measurement from the 8 measurements for each individual layer calculated. Following, these
cross-sectional averages were then averaged for the animal’s overall muscular and mucosa
average. The averages of each of the animals for each group were displayed in the figures
discussed below and investigated for significance in comparison to other groups.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism Version 9. The p-value was
set a-priori at p>.05. Data was examined for outliers using a ROUT test. Equal variance was
assessed through the use of Kolmogorov-Smirnov test. A one-way Analysis of Variance
(ANOVA) was used to determine statistical significance between the three groups for the shortchain fatty acid and intestinal thickness studies.
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RESULTS
Microbiota expression in mice
The CLC Workbench, per Qiagen, was used to compute the alpha diversity, beta
diversity, and PERMONOVA for the three groups in each gender. Alpha diversity is used to
illustrate diversity within each sample. It is sometimes referred to as richness amongst the
control, VA, and BTBR groups. An alpha diversity analysis was run for both female and male
separately. A Shannon entropy test evaluates the alpha-diversity within sample groups (Figure
1A) and does indicate that there was sufficient sequencing to explore microbiota investigations
for each sample in the males. Beta diversity analysis was used to illustrate an overall evaluation
of the different taxonomy between the three groups. The Bray-Curtis analysis indicates that
differing central tendency measures can be observed for each group in the males (Figure 1B). A
PERMONOVA is an analysis of variance that compares all groups side-by-side to display
distinct differences in the sample groups by determining an overall level of significance between
microbiota expressions. Using the Bray Curtis data, the PERMANOVA does indicate that both
the BTBR and VA groups demonstrate a significantly different microbiota profile (p<.05) when
compared to the wild-type control group in the males (Table 1).
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B

Figure 1: (Panel A) Male alpha diversity across groups (Control N=6 red, BTBR N=8 green, VA
N=5 purple). Each line represents a sample that was analyzed in its respective group. The BTBR
group has the lowest richness, while on average, valproic acid has the highest. (Panel B) The 3-D
Bray-Curtis graphic shows the points of central tendency for each group (N=6 red), VA (N=5
purple), and BTBR (N=8 green) male groups.

Table 1. PERMONOVA comparing male Control (Type 1), BTBR (Type 2), and Valproic Acid
(Type 3) groups. The p-values were all <0.05 to indicate significance.
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In females, the Shannon entropy analysis indicated that there was sufficient sequencing
that demonstrated richness within each sample to warrant further evaluation in the female
samples (Figure 2A). The Bray-Curtis measurement demonstrated unique measures of central
tendency for each group (Figure 2B). Analysis using PERMANOVA did indicate in females
that the wild-type control group did express a significantly different microbiota expression
profile when compared to BTBR and VA mice (Table 2).

A

B

Figure 2: (Panel A) Female alpha diversity across groups (Control N=14 red, BTBR N=14
green, VA N=14 purple). Each line represents a single sample with color indicating the group.
The BTBR group has the lowest richness, while on average, valproic acid has the highest
richness. (Panel B) The 3-D Bray-Curtis graphic shows the differentiation between the control
(N=14; red dots), VA (N=14; purple dots), and BTBR (N=14; green dots) mice.
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Table 2. PERMONOVA comparing female wild type control (Type 1), BTBR (Type 2), and
valproic acid (Type 3) groups. Significance was found using p <0.05.

SCFA expression in animal models
Gas chromatography was used to measure acetate, propionate, butyrate, and valerate
levels in male mice. The data shown found the quantity of nanomoles for each SCFA per
milligram of freeze-dried feces used for analysis (80 mgs). There were no significant differences
found for acetate, propionate or butyrate in either BTBR or VA male mice when compared to
control male mice (Figure 3A-C). Valproic acid was significantly different in the BTBR group
when compared to control wild-type mice using an ANOVA for analysis (Figure 3D).
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Figure 3: (Panel A) Nanomoles (nmol) of acetate per 80 milligrams (mg) of feces from male
mice (N=13 unfilled bars), BTBR (N=18 black bars), and VA (N=22 gray bars). (Panel B)
Nanomoles of propionate in 80 mgs of feces. (Panel C) Nanomoles of butyrate found per 80 mgs
of feces. (Panel D) Nanomoles of valerate in 80 mgs of feces. Asterisks (*) indicates a p-value
<.05.
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Short chain fatty acid levels were also compared between female groups. Interestingly, a
one-way ANOVA found that acetate (p<.05) and propionate (p<.01) demonstrated significant
differences in the BTBR group when compared to C57 wild type control mice (Figure 4A and
4B). Butyrate nor valproic acid did not demonstrate any significant differences when compared
to the wild type control mice (Figure 4C and 4D).
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Figure 4: (Panel A) Nanomoles (nmol) of acetate per 80 milligrams (mg) of feces from female
mice (N=13 unfilled bars), BTBR (N=14 black bars), and VA (N=15 gray bars). (Panel B)
Nanomoles of propionate in 80 mgs of feces. (Panel C) Nanomoles of butyrate found per 80 mgs
of feces. (Panel D) Nanomoles of valerate in 80 mgs of feces (N=13 control, N=13 BTBR, and
N=15 VA). Asterisks (*) indicates p <.05 and ** is p<.01.
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Mucosal and Muscular Layer thickness in Models
Two layers of the colon were measured to determine if intestinal pathology could be
found in the models. The tunica mucosa is the layer closest to the lumen, while the tunica
muscularis is the smooth muscle layer. Representative images of the colon for each group
including C57 wild type control (Figure 5A), BTBR (Figure 5B) and VA female mice (Figure
5C) are show in Figure 5. Neither layer demonstrated any significant differences in thickness in
either the BTBR or VA group when compared to the wild type control mice for the males
(Figure 5D and 5E).
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Figure 5: Representative images of the colon used for image analysis from C57 male (panel A),
BTBR male (panel B) and VA male (panel C). Panel D is the thickness of the tunica muscularis
of C57 control (N=11; unfilled bars), BTBR (N=9; filled bars), and VA (N=10; gray bars)
showing no significance between the average muscular measurements (µm) between the groups.
Panel E is the thickness of the intestinal mucosal layer of male C57 control (N=11; unfilled
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bars), BTBR (N=9; filled bars), and VA (N=10; gray bars) showing no significance between the
average mucosa measurements (µm) taken for each group in the males.

Tunica muscularis and tunica mucosa thickness were measured in the C57 wild type
control, BTBR and VA female mice. Representative images are shown for each group in Figure
6A-C. The tunica mucularis nor the tunica mucosa demonstrated any significant differences in
the females between any groups (Figure 6D and 6E).
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Figure 6: Representative images of the colon used for image analysis from C57 (panel A),
BTBR (panel B) and VA (panel C). Panel D is the thickness of the tunica muscularis of C57
control (N=10; unfilled bars), BTBR (N=10; filled bars), and VA (N=10; gray bars) showing no
significance between the average muscular measurements (µm) between the groups. Panel E is
the thickness of the intestinal mucosal layer of female C57 control (N=10; unfilled bars), BTBR
(N=10; filled bars), and VA (N=10; gray bars) showing no significance between the average
mucosa measurements (µm) taken for each group in the females.
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DISCUSSION
The study shown here was designed to evaluate whether intestinal pathology is associated
with potential mouse models that could be used to investigate ASD. Microbiome expression
patterns, short-chain fatty acid production, and intestinal thickness were assessed to compose an
exhaustive picture of the overall gut health of these mouse models. While the concept and even
some of the experimentations aren’t novel, the use of all three methods to create a
comprehensive examination of gut pathology in the same animals has never been done.
Using 16S ribosomal RNA sequencing to identify bacterial taxonomic expression levels
from feces revealed vastly different expression profiles between the models and the control mice.
The alpha diversity shows a significant differentiation in the richness across samples.
Interestingly, the BTBR model, in both males and females, depicts the lowest richness while the
valproic acid treated control group exhibits the highest diversity within a sample. It can be
concluded that individual samples within groups have similar diversity. The BTBR group and
control group are notably the most different in measures of central tendency shown by the beta
diversity plots, while the VA group lies somewhere in between.
The intestinal pathology data found that there is no significant difference concerning
muscular and mucosal widths across all three groups. It is possible that pathological differences
of layer thickness would not be affected by the alteration of bacterial phyla found in the lumen.
While we determined that microbial communities are significantly different, the short chain fatty
acid profiles were not significantly different in the VA model and only marginally different in
the BTBR; thus, making it acceptable that pathology of the intestinal layers may not have been
present. These findings certainly question the validity of the VA animals as a model of social
behavioral deficits since they are created from the control animals.
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With multiple physiological and psychological functions affected by the microbiome, the
direction of treatment for ASD and other disorders may lie in the restoration of a normal
microbiome. The microbiome can be affected by multiple factors such as diet, probiotics,
prebiotics, antibiotics, one’s psychiatric health, etc. More clinical studies need to be performed in
order to completely understand the complexities involved in the gut and brain interactions. It is
known that the presence of unfavorable bacteria in the gut can negatively impact gastrointestinal
health as well as behavior. For example, antibiotics lead to a less diverse microbiome as well as
impact mood (Karakan, 2021). Prebiotics have been shown to improve gut microbiome by
supplying dietary fiber that results in the production of healthy SCFAs. However, this type of
treatment relies solely on the bacteria already present within the microbiome. In cancer research
in particular, probiotic usage has been shown to influence microbiome makeup as well. Changes
in the gut can promote expression of anti-inflammatory cytokines, while decreasing the
production of pro-inflammatory ones. The characterization of the “ideal” microbiome in humans
is unclear and needs more conclusive information especially regarding behavior.
There have been extensive studies done concerning diet and its effects on the microbiome
in ASD children; specifically, the ketogenic diet (KD) which is also used to treat epilepsy.
Factors such as anti-inflammatory activity, oxidative stress, metabolism, neurotransmitter
regulation, and GI symptoms are much approved alikely due to the altered gut microbial
composition restored by a KD (Li, 2021). The long-term effects of KD on ASD patients are
unknown. Further studies need to be done to identify future reactions.
Limitations
Some experimental limitations could be found in this study. Ribosomal sequencing using
variable regions of the 16S area can be considered a limitation. The variable region can only
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identify to the genus level. A PERMONOVA analysis was run to determine initially if male and
female mice could be grouped together. However, as shown in the appendix, male and female
control microbiome profiles were significantly different indicated by a p-value <0.05 (Appendix
Table 2). Additionally, the male groups were obtained in two different time periods and the
microbiome RNA sequencing data were obtained from two different sequencing runs. Analysis
was performed to determine if results would be affected if both batches were grouped together.
To illustrate the microbiome differences that were found, a Bray-Curtis beta diversity analysis
and PERMONOVA on the Qiagen CLC Workbench was performed to compare batch one
controls to batch two controls, batch one VA to batch two, and batch one BTBR to batch two
(Appendix Figures 2-4; Appendix Tables 4-6). From the results, the microbiome profiles of the
batch controls, VA, and BTBR samples are distinctly different. In the same way, a p-value<0.05
indicates significant differences. Therefore, the data shown in the manuscript body only includes
the most recent batch of males instead of the initial combined.
The mice models themselves used served as a limitation. This is because there is no
universally accepted animal model that has been found for ASD study use. Studies observing
strains that exhibit behaviors such as social behavior deficits or excessive grooming such as the
BTBR and VA models are used. It does not eliminate the issue that the mechanisms of these
models are not fully understood. Additionally, the BTBR model is a knock-out of an inositol
receptor and while C57 mice are used as control mice throughout the literature, it is quite
possible that C57 mice are not the appropriate group to use for comparisons.
Another limitation worthy to note is the use of only the colon for evaluation of intestinal
pathology. Some studies show thickness of multiple areas of the digestive tract including the
jejunum, ileum and even the stomach. We chose to only evaluate the part of the digestive tract
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that housed the greatest diversity of bacterial species. The number of measurements per
muscular and mucosal layer were based on samples that had been obtained from a relatively
small study number. Additionally, the measures of the thinnest and thickest layer of the colon
were obtained by observational methods. A representative image for each animal is shown in
Appendix Figure 7. Approximately 1,000 images were taken, and 5,500 measurements were
obtained for both the muscular and mucosal layers. However, it would enhance the study to do
other intestinal areas.
Future studies
Future studies are needed for the identification of specific biomarkers contributing to
ASD. The microbiome analysis of the different groups created expression differential abundance
tables for the different taxonomy for both the male and female comparisons. An exhaustive list
of the identified taxonomy related OTU comparisons can be found for the BTBR and VA to the
wild-type control group. Each genus, phylum, order, etc. of identified bacterial taxonomy is
included in the table with a p-value that indicates if there is a significant difference between each
of the three groups. The next step is to identify specific taxonomy that are significantly different
between the VA or BTBR group and the control group. Identification of these bacterium could
lead to specific therapies that target and/or promote production. Additionally, examination of the
maternal gut microbiota would be a valid future investigation. It can be inferred from this initial
study that there is reason to analyze mother-child gut microbiome profiles, as the valproic acid
treated offspring resulted in social deficits and excessive repetitive behaviors. Also, many other
markers including glia activation and serotonin expression in the gut could be evaluated to
identify a more specific pathology of the model.
Conclusions
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The importance of a healthy microbiome may be incredibly important to understanding
and treating ASD. Animal studies may provide a viable route to examine the relationship
between the gut brain axis. It was shown that the microbiome profiles of control samples and
mice models of abnormal social behaviors for both males and females were significantly
different. However, there were no pathological differences in intestinal anatomy nor were
consistent changes found for short chain fatty profiles between the groups. It is possible that
pathological levels of aberrant bacterial expression are not reached in these models. However,
there are multiple markers that could be investigated to determine the extent of gut pathology in
behavioral studies. A need for further clarity remains to understand the complexities of ASD
pathology.
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APPENDIX
Appendix Table 1: Breakdown of muscular and mucosal measurements.

Animal
C50M
C53M
C54M
C55M
C59M
C60M
C63M
C139M
C2375M
C2376M
C2377M

Number of
Cross-Sections
6
3
7
3
3
2
2
4
8
8
7

Number of
Images
20
14
26
17
10
9
8
19
16
20
17

Number of
Muscular
Measurements
49
30
56
34
24
18
16
38
62
52
54

Number of
Mucosal
Measurements
52
30
56
34
24
18
16
42
62
52
54

V72M
V75M
V76M
V77M
V83M
V85M
V86M
V622M
V624M
V625M

4
4
5
5
4
3
3
6
5
6

23
13
16
12
17
10
14
21
20
15

46
32
44
40
38
24
30
40
44
46

46
32
44
40
38
24
32
44
44
46

B85M
B86M
B89M
B92M
B93M
B513M
B5128M
B5129M
B5130M

8
9
8
8
8
8
6
8
8

21
19
16
19
23
21
14
21
17

58
68
64
62
58
66
42
66
56

58
68
64
62
60
66
42
66
56

C95F

5

21

48

50
44

45

C97F
C98F
C100F
C125F
C126F
C127F
C128F
C2378M
C2379M

3
4
2
3
8
3
3
7
6

8
16
10
14
25
11
12
25
13

24
33
18
30
64
19
24
56
44

24
38
20
32
64
22
24
56
44

V105F
V106F
V107F
V108F
V110F
V111F
V113F
V129F
V133F
V637F

4
4
5
7
4
3
6
6
7
7

26
19
25
37
13
10
18
35
25
16

44
42
50
71
28
18
40
56
54
56

52
42
52
78
30
22
48
76
54
56

B115F
B116F
B118F
B119F
B121F
B122F
B135F
B136F
B137F
B5122F

8
8
6
8
8
7
9
8
9
7

29
22
15
18
16
15
17
19
19
19

61
60
42
56
62
52
66
60
66
52

61
60
42
56
62
52
66
60
66
52
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Appendix Table 2: PERMONOVA comparing male controls (Type 1) to female controls (Type 2). P-value <0.05 indicates
significant difference in microbiome profiles.

Appendix Figure 1: The 3-D Bray-Curtis graphic shows the differentiation between the
batch 1 control (N=7 red), and BTBR (N=7 green), and VA (N=7 purple) male groups.

Appendix Table 3: PERMONOVA comparing batch 1 control (Type 1) to BTBR (Type 2), to VA (Type 3) males. All p-values
<0.05 indicate significant difference.
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Appendix Figure 2: The 3-D Bray-Curtis graphic shows the differentiation between the
batch 1 control (N=7 green) and batch 2 control (N=6 purple) male groups.

Appendix Table 4: PERMONOVA comparing batch 1 control (Type 1) to batch 2 control (Type 2) males.
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Appendix Figure 3: The 3-D Bray-Curtis graphic shows the differentiation between the
batch 1 VA (N=7 green) and batch 2 VA (N=7 purple) male groups.

Appendix Table 5: PERMONOVA comparing batch 1 VA (Type 1) to batch 2 VA (Type 2) males.
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Appendix Figure 4: The 3-D Bray-Curtis graphic shows the differentiation between the
batch 1 BTBR (N=7 green) and batch 2 BTBR (N=8 purple) male groups.

Appendix Table 6: PERMONOVA comparing batch 1 BTBR (Type 1) to batch 2 BTBR (Type 2) males.

Appendix Figure 7: Representative image for all samples used for intestinal lumen
measurements and accompanying image.
CrossAnimal
Gender
Section
Image

49

50

C50M

Male

1

C53M

Male

2

C54M

Male

1

50

51

C55M

C59M

C60M

Male

1

Male

1

Male

1

51

52

C63M

Male

1

C139M

Male

4

C2375M

Male

1

52

53

C2376M

Male

2

C2377M

Male

6

V72M

Male

1

53

54

V75M

V76M

V77M

Male

1

Male

Male

1

1

54

55

V83M

Male

1

V85M

Male

1

V86M

Male

2

55

56

V622M

Male

2

V624M

Male

5

V625M

Male

3

56

57

B85M

Male

2

B86M

Male

7

B89M

Male

2

57

58

B92M

Male

3

B93M

Male

7

B513M

Male

6

58

59

B5128M

Male

3

B5129M

Male

1

B5130M

Male

5

59

60

C95F

Female

1

C97F

Female

2

C98F

Female

1

60

61

C100F

Female

2

C125F

Female

3

C126F

Female

1

61

62

C127F

Female

1

C128F

Female

1

C2378F

Female

2

62

63

C2379F

Female

4

V105F

Female

3

V106F

Female

1

63

64

V107F

Female

5

V108F

Female

6

V110F

Female

4

64

65

V111F

Female

3

V113F

Female

2

V129F

Female

5

65

66

V133F

Female

1

V637F

Female

1

B115F

Female

2

66

67

B116F

Female

4

B118F

Female

6

B119F

Female

3

67

68

B121F

Female

5

B122F

Female

6

B135F

Female

7

68

69

B136F

Female

5

B137F

Female

7

B5122F

Female

5

69

70

70

